TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02049437

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tocilizumab
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tocilizumab
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized 1:1 to one of the following arms:~ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.~ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28.
Study: NCT00740519

Intervention type: DRUG
Intervention: insulin detemir
Description: Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
Study: NCT02831400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking test
Description: Walking test to increase cardiac output, maximum 12 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Meal
Description: After the walking test, volunteers eat a standard warm meal
Study: NCT04144985

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
Description: Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
Study: NCT04491734

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: maltosyl-isomalto-oligosaccharides (MIMO)
Description: Digestion-resistant carbohydrate, ISOT-101, a specific formulation of maltosyl-isomalto-oligosaccharides (MIMO), that serves as a prebiotic, feeding selected bacteria that commonly inhabit the human GI tract.
Study: NCT03231345

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided IJ
Description: IV catheter placement
Study: NCT04144985

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
Description: Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visual analog scale (VAS) of pain to evaluate the discomfort participants experience.
Description: Eyelid retraction was performed with one of the three methods (eyelid speculum, unimanual eyelid retraction or cotton tipped applicator assisted eyelid retraction) and participants were then asked to rate their discomfort during the procedure with a visual analog scale (VAS) of pain.
Study: NCT03950908

Intervention type: OTHER
Group type: OTHER
Intervention: Single bite biopsy technique
Description: During biopsy collection one specimen will be retrieved during a single passage of the biopsy forceps.

Intervention type: OTHER
Group type: OTHER
Intervention: Double bite biopsy technique
Description: During biopsy collection two specimens will be retrieved during a single passage of the biopsy forceps.
Study: NCT04135924

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: physical exercise and respiratory muscle training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: physical exercise and respiratory muscle training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: physical exercise and respiratory muscle training
Study: NCT03207425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Each subject will receive a single dose of EDP 305 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Each subject will receive a single dose of EDP 305 on Day 1.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EDP 305
Description: Each subject will receive a single dose of EDP 305 on Day 1.
Study: NCT03424928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule
Description: per os,capsule,4mg,1 capsule per period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide 4 MG Oral Capsule-Pomalyst
Description: per os,capsule,4mg,1 capsule per period
Study: NCT01822678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eslicarbazepine Acetate
Description: Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01905410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injection
Description: VVZ-149 in water for injection
Study: NCT03231345

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Ultrasound-guided Internal Jugular vein
Study: NCT03439995

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Open lung protective ventilation
Description: Higher PEEP, lower tidal volume mechanical ventilation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: Lower PEEP, standard tidal volume mechanical ventilation
Study: NCT04592653

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa
Description: IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa
Description: IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin alfa
Description: IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: IV infusion over 30 minutes
Study: NCT01905410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VVZ-149 Injection
Description: VVZ-149 in water for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: water for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: water for injection
Study: NCT04041375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iNSPiRED
Description: The peer intervention will include approximately 5 to 6 contacts over a 3-month period. Peer navigators are responsible for providing emotional and social support, normalizing the difficulty of living with DM, modeling help-seeking behaviors, and connecting patients with VHA and/or CBOs to address mental health and DM self-management needs. Peer coaches are not responsible for health education directly; rather, they encourage patients to use appropriate programs in which mental health and DM self-management services are provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Veterans randomized to the usual care condition will be encouraged to follow-up with their primary care provider and/or specialty providers for management of their health conditions. They will also receive a packet of printed information that includes a list of self-management support resources in the VHA and the local community. They will receive no further specific recommendations
Study: NCT04203381

Intervention type: DEVICE
Group type: OTHER
Intervention: GnRH Agonist
Description: Forty participants who are transgender and who have been prescribed a gonadotropin-releasing hormone (GnRH) agonist by their physician will undergo magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), dual-energy x-ray absorptiometry (DXA) and peripheral quantitative computed tomography (pQCT) scans at baseline, at 12 months and at 24 months after initiation of the GnRH agonist therapy. This longitudinal observational study of two cohorts seeks to identify significant changes in bone marrow adiposity and bone density over 24 months. The same assessments will be obtained in 40 healthy control subjects matched for age, race/ethnicity and body mass index, all factors that are known to influence skeletal outcomes. The evaluations of bone marrow adiposity will be correlated with bone density measurements and the assessments of mood (validated anxiety and depression scales) and health-related quality of life, before and after pubertal blockade.
Study: NCT00985816

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus Reuteri
Description: L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT00943124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
Description: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524B (ER niacin (+) laropiprant (+) simvastatin)
Description: Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524A (ER niacin + laropiprant)
Description: Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0524A (ER niacin + laropiprant)
Description: Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
Study: NCT02071927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Single-agent CB-839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-839
Description: Single-agent CB-839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-Aza
Description: CB-839 in combination with standard dose azacitidine
Study: NCT04680156

Intervention type: DRUG
Intervention: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Description: No treatment to be administered - Observational only

Intervention type: DRUG
Intervention: Previously treated with EN3835 up to 1.74 mg or Placebo in EN3835-210 or the pivotal phase 3 studies
Description: No treatment to be administered - Observational only
Study: NCT03536897

Intervention type: RADIATION
Intervention: IORT
Description: Intraoperative radiation therapy with INTRABEAM system to a dose of 20 Gy
Study: NCT01663168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifabutin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifabutin
Study: NCT04911413

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Description: The drug used in this RCT is tranexamic acid. We used three different doses of TXA in three groups.
Study: NCT02185755

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Internet-Based Glucose Monitoring System
Study: NCT00024258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arsenic trioxide
Study: NCT00111137

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rHuEPO
Description: rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darbepoetin alfa
Description: 4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
Study: NCT02902055

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Blocking Agents
Description: Neuromuscular blockae

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotonic saline
Description: Placebo
Study: NCT03493035

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography (3D CTA)
Description: CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Computed tomography angiography (3D CTA)
Description: CTA scans data in DICOM format was used to morphometric analysis of aneurysmal and non-aneurysmal MCA bifurcations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial color-coded sonography (TCCS)
Description: TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.

Intervention type: DIAGNOSTIC_TEST
Intervention: Transcranial color-coded sonography (TCCS)
Description: TCCS was used to assess of hemodynamic parameters of aneurysmal and non-aneurysmal MCA bifurcations.
Study: NCT03693833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabidiol
Description: Cannabidiol (CBD) tablets of 10mg each

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Oral Placebo tablets of 10mg each
Study: NCT00506012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T2000
Description: T2000 at doses of 200 mg a day to 1000 mg a day
Study: NCT03294317

Intervention type: DEVICE
Intervention: His bundle pacing
Description: Medtronic SelectSecure SureScan MRI model 3830 lead
Study: NCT03545399

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ulva Lactuca
Description: The dose was taken with a glass of water during the evening meal once daily
Study: NCT04541225

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NUV-422
Description: NUV-422 is an investigational drug for oral dosing.
Study: NCT03281564

Intervention type: OTHER
Intervention: Quality of life after Essure® removal
Description: Questionnaire to assess the quality of life 1, 3, 6 and 12 months after laparoscopic removal of Essure® device
Study: NCT00335556

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study: NCT02185755

Intervention type: DRUG
Group type: OTHER
Intervention: Normal Medication Positive Control
Study: NCT03464461

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketorolac
Description: IV drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketorolac
Description: IV drug
Study: NCT01087697

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neo-Urinary Conduit
Description: Implantation with the autologous Neo-Urinary Conduit
Study: NCT01509508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Immediate ARV treatment initiation with TDF/FTC/EFV
Description: All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.~The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD.
Study: NCT03545399

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The dose was taken with a glass of water during the evening meal once daily
Study: NCT02922582

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoTXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoTXA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DepoTXA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic Acid
Study: NCT02571634

Intervention type: DRUG
Group type: OTHER
Intervention: Lazanda
Description: Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
Study: NCT03680716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine injection
Description: Saphenous nerve block with 20ml of ropivacaine 0.5% and IPACK block with 30ml of ropivacaine 0.2% (total dose of 160 mg).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine injection
Description: Periarticular infiltration of 80 ml ropivacaine 0.2% (total dose of 160mg).
Study: NCT01134991

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Study: NCT01509508

Intervention type: OTHER
Group type: OTHER
Intervention: South African recommendation guided ARV (TDF/FTC/EFV) initiation
Description: HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:~* CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms~* WHO clinical stage 3 or 4 irrespective of CD4 count~* MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD.
Study: NCT01134991

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical Minocycline Foam FXFM244
Description: FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
Study: NCT03879486

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intrarectal povidone-iodine cleansing plus formalin disinfection of needle tip during transrectal ultrasound guided prostate biopsy
Description: The examiner will use a gauze soaked and saturated with iodopovidone and perform a mechanical friction motion on the anterior wall of the rectum, at least 5 times from one margin to another of the prostate laterally-laterally. A period of two (2) minutes shall be waited from the prophylactic cleaning of the rectum to the beginning of the biopsy. The examiner will use a technique of disinfecting the 10% formaldehyde biopsy needle without manual contact by soaking the distal 3 cm of the needle directly into a vial containing the bactericidal solution between obtaining the different fragments. An individual bottle will be used for each patient
Study: NCT00777855

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin plus rifampin
Description: warfarin 7.5mg po x 1; rifampin 600mg IV x 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: warfarin 7.5mg po x 1
Study: NCT02473393

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPS-2071 tablet
Study: NCT02938845

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger's State-Trait Anxiety Inventory(STAI )
Description: State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spielberger's State-Trait Anxiety Inventory(STAI )
Description: State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: total laparoscopic hysterectomy(TLH)